

**HHS PUBLIC ACCESS**

Author manuscript

*J Bone Miner Res.* Author manuscript; available in PMC 2015 March 16.

Published in final edited form as:

*J Bone Miner Res.* 2014 June ; 29(6): 1456–1465. doi:10.1002/jbmr.2158.**Increased IL-6 Expression in Osteoclasts Is Necessary But Not Sufficient for the Development of Paget's Disease of Bone****Jumpei Teramachi<sup>1</sup>, Hua Zhou<sup>2</sup>, Mark A Subler<sup>3</sup>, Yukiko Kitagawa<sup>1</sup>, Deborah L Galson<sup>4</sup>, David W Dempster<sup>2</sup>, Jolene J Windle<sup>3</sup>, Noriyoshi Kurihara<sup>1</sup>, and G David Roodman<sup>1,5</sup>**<sup>1</sup>Department of Medicine, Hematology Oncology, Indiana University, Indianapolis, IN<sup>2</sup>Department of Pathology, College of Physician and Surgeons, Columbia University, New York, NY<sup>3</sup>Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA<sup>4</sup>Department of Medicine, Hematology Oncology, University of Pittsburgh, Pittsburgh, PA<sup>5</sup>Department of Medicine, Richard L. Roudebush VA Medical Center, Indianapolis, IN**Abstract**

Measles virus nucleocapsid protein (MVNP) expression in osteoclasts (OCLs) and mutation of the SQSTM1 (p62) gene contribute to the increased OCL activity in Paget's disease (PD). OCLs expressing MVNP display many of the features of PD OCLs. Interleukin-6 (IL-6) production is essential for the pagetic phenotype, because transgenic mice with MVNP targeted to OCLs develop pagetic OCLs and lesions, but this phenotype is absent when MVNP mice are bred to IL-6<sup>-/-</sup> mice. In contrast, mutant p62 expression in OCL precursors promotes receptor activator of NF-κB ligand (RANKL) hyperresponsivity and increased OCL production, but OCLs that form have normal morphology, are not hyperresponsive to 1,25-dihydroxyvitamin D<sub>3</sub> (1,25-(OH)<sub>2</sub>D<sub>3</sub>), nor produce elevated levels of IL-6. We previously generated p62<sup>P394L</sup> knock-in mice (p62KI) and found that although OCL numbers were increased, the mice did not develop pagetic lesions. However, mice expressing both MVNP and p62KI developed more exuberant pagetic lesions than mice expressing MVNP alone. To examine the role of elevated IL-6 in PD and determine if MVNP mediates its effects primarily through elevation of IL-6, we generated transgenic mice that overexpress IL-6 driven by the tartrate-resistant acid phosphatase (TRAP) promoter (TIL-6 mice) and produce IL-6 at levels comparable to MVNP mice. These were crossed with p62KI mice to determine whether IL-6 overexpression cooperates with mutant p62 to produce pagetic lesions. OCL precursors from p62KI/TIL-6 mice formed greater numbers of OCLs than either p62KI or TIL-6 OCL precursors in response to 1,25-(OH)<sub>2</sub>D<sub>3</sub>. Histomorphometric analysis of bones from p62KI/TIL-6 mice revealed increased OCL numbers per bone surface area compared to wild-type

© 2014 American Society for Bone and Mineral Research

Address correspondence to: G David Roodman, MD, PhD, Department of Medicine, Hematology Oncology, School of Medicine, Indiana University, 980 West Walnut Street, R3, Indianapolis, IN 46202, USA. [groodman@iu.edu](mailto:groodman@iu.edu).

Authors' roles: GDR and NK designed study and wrote the paper; JT, YK, and NK performed the experiments; MAS and JJW generated the transgenic mice; and HZ and DWD performed histological section and analysis. JJW, DWD, DLG, GDR, and NK did the data interpretation. All authors approved the submission of manuscript.

**Disclosures** GDR is a consultant to Amgen. All other authors state that they no conflicts of interest.

(WT) mice. However, micro-quantitative CT ( $\mu$ QCT) analysis did not reveal significant differences between *p62KI/TIL-6* and WT mice, and no pagetic OCLs or lesions were detected in vivo. Thus, increased IL-6 expression in OCLs from *p62KI* mice contributes to increased responsiveness to 1,25-(OH) $_2$ D $_3$  and increased OCL numbers, but is not sufficient to induce Paget's-like OCLs or bone lesions in vivo.

## Keywords

P62; MVNP; IL-6; PAGET'S DISEASE OF BONE; OSTEOCLASTS

## Introduction

The primary cellular abnormality in Paget's disease (PD) resides in the osteoclast (OCL).<sup>(1-3)</sup> OCLs are abundant in Paget's lesions, and are larger, contain increased nuclei/OCL, have increased bone resorbing capacity/OCL, increased 1,25-dihydroxyvitamin D $_3$  (1,25-(OH) $_2$ D $_3$ ) and receptor activator of NF- $\kappa$ B ligand (RANKL) responsiveness, and secrete high levels of interleukin 6 (IL-6), compared to normal OCLs.<sup>(4,5)</sup> Pagetic OCLs frequently express the measles virus nucleocapsid protein (MVNP),<sup>(6)</sup> which we have shown induces high levels of IL-6 expression in both human and mouse OCLs, and results in the development of pagetic OCLs and pagetic bone lesions in mice in vivo.<sup>(7,8)</sup> Further, high levels of IL-6 can induce TAF12, a vitamin D receptor (VDR) coactivator, in OCL precursors, which increases their responsiveness to 1,25-(OH) $_2$ D $_3$ . Importantly, knockout of IL-6 in MVNP mice results in loss of their capacity to form pagetic lesions and OCLs,<sup>(9)</sup> suggests that IL-6 is required for *MVNP* to induce the development of PD.

There is also a genetic component to the etiology of PD, with up to 5% to 10% of all Paget's patients carrying a germline mutation in the *SQSTM1/p62* gene.<sup>(10)</sup> Expression of *p62<sup>P392L</sup>*, the most frequent mutation in *p62* linked to PD in OCL precursors confers hyperresponsivity to RANKL but not 1,25-(OH) $_2$ D $_3$ , does not increase IL-6, and does not induce hypermultinucleated OCLs that occur in PD. Further, we found that knock-in mice (*p62KI*) carrying a *p62<sup>P394L</sup>* mutation (the murine equivalent of the most common human PD mutation, *p62<sup>P392L</sup>*) had modestly increased OCL numbers and developed mild osteopenia, but did not develop pagetic lesions.<sup>(11,12)</sup> However, when we crossed the *p62KI* and *MVNP* mice, the resulting *p62KI/MVNP* mice developed exuberant bone lesions that closely resembled PD lesions.<sup>(9)</sup> In addition, OCL precursors isolated from *p62KI/MVNP* mice were hyperresponsive to both RANKL and 1,25-(OH) $_2$ D $_3$ , expressed elevated IL-6, and formed hypermultinucleated OCLs that were similar to OCL from PD patients. These results suggest that increasing IL-6 expression in OCLs of *p62KI* mice may induce pagetic lesions and a pagetic phenotype in *p62KI* mice in vivo.

To test this hypothesis, we generated transgenic mice overexpressing IL-6 in OCLs driven by the tartrate-resistant acid phosphatase (TRAP) promoter (*TIL-6* mice), and crossed them with the *p62KI* mice. OCL precursors from *p62KI/TIL-6* mice were hyperresponsive to 1,25-(OH) $_2$ D $_3$  and RANKL compared to wild-type (WT). However, although these OCL

had increased numbers of nuclei/OCL, the nuclear number was lower than in *MVNP* mice. Further, *p62KI/TIL-6* mice did not form pagetic OCLs or bone lesions in vivo.

PD is characterized by increases in both osteoclast and osteoblast activity; we found that both of these occur in *MVNP* but not the *p62KI* mice we generated. These results raise the question of why osteoblast activity is not induced in our previously reported *p62KI* mice. We found that in contrast to *MVNP* mice, osteoblasts from *p62KI* mice expressed much lower levels of Runx2 and osterix, transcription factors necessary for osteoblast differentiation, and higher levels of Dickkopf 1 (DKK1), a Wnt antagonist. Treatment of osteoblast precursors from *p62KI* mice with IL-6 did not increase Runx2 or osterix and did not decrease DKK1 levels. These results suggest that *MVNP* expression in OCL induces other factors in addition to IL-6, which are necessary for the development PD lesions in mice.

## Subjects and Methods

### Generation of TRAP-*IL6* transgenic mice

All studies were approved by the Institutional Animal Care and Use Committees at Indiana University School of Medicine, the University of Pittsburgh School of Medicine, and Virginia Commonwealth University. To generate the TRAP-*IL-6* transgene construct, a 1.1-kb EcoRI endonuclease fragment containing a human *IL-6* cDNA (ATCC cDNA number 67153; American Type Culture Collection [ATCC], Manassas, VA, USA) was inserted into the unique EcoRI site of the pKCR3-mTRAP vector.<sup>(13,14)</sup> pKCR3-mTRAP contains 1.9 kb of the mouse TRAP gene promoter and 5'-untranslated region (UTR), in addition to rabbit  $\beta$ -globin intron 2 and its flanking exons (for efficient transgene expression). A 4.2-kb injection fragment was then excised from the TRAP-*IL-6* construct with XhoI restriction endonuclease, and transgenic mice were generated by standard methods in a CB6F1 (C57Bl/6  $\times$  Balb/c) genetic background.<sup>(15)</sup> *p62KI* mice carrying a proline-to-leucine mutation at residue 394 (equivalent to human *p62*<sup>P392L</sup>) have been described.<sup>(11)</sup> TRAP-*MVNP* transgenic mice have also been described.<sup>(8)</sup>

### OCL formation from total transgenic mouse bone marrow

Bone marrow cells flushed from long bones of WT, *p62KI*, *TIL-6*, *p62KI/TIL-6*, or *MVNP* mice were cultured in 96-well plates ( $2 \times 10^5$  cells/well) with various concentrations of 1,25-(OH)<sub>2</sub>D<sub>3</sub> (Teijin Pharma, Tokyo, Japan) or RANKL (R&D, Minneapolis, MN, USA) as described. The end of cultures, cells were stained for TRAP using a leukocyte acid phosphatase kit (Sigma, St. Louis, MO, USA), and TRAP-positive cells ( $> 3$  nuclei/cell) were scored as OCLs.

### OCL formation from purified osteoclast precursors

OCL formation from CD11b<sup>+</sup> cells was performed as described.<sup>(16)</sup> Nonadherent cells were harvested and enriched for CD11b<sup>+</sup> mononuclear cells using the Miltenyi Biotec (Auburn, CA, USA) MACS (Magnetic Cell Sorting) system. CD11b<sup>+</sup> cells then were cultured in  $\alpha$  modified essential medium ( $\alpha$ -MEM) containing 10% fetal calf serum (FCS) plus 10 ng/mL of macrophage colony-stimulating factor (M-CSF; R&D Systems, Minneapolis, MN, USA)

for 3 days to generate a population of enriched early OCL precursors. These cells were then cultured in  $\alpha$ -MEM containing 10% FCS in the presence of 1,25-(OH)<sub>2</sub>D<sub>3</sub> or RANKL for 3 to 4 days to generate OCLs. The cells were then stained for TRAP and TRAP-positive cells (3 nuclei/cell) were scored as OCLs.

### **Bone resorption assays of cultured OCLs**

Bone marrow cells were cultured on mammoth dentin slices (Wako, Osaka, Japan) in  $\alpha$ -MEM containing 10% FCS and 1,25-(OH)<sub>2</sub>D<sub>3</sub> ( $1 \times 10^{-8}$  M) or RANKL (100 ng/mL). After 14 days of culture, the cells were removed, the dentin slices stained with acid hematoxylin, and the areas of dentin resorption determined using image-analysis techniques (NIH ImageJ System).

### **Immunoblotting of OCL precursor lysates from WT, p62KI, TIL-6, or p62KI/TIL-6 mice**

Total proteins were extracted from formed OCL and loaded on SDS gels (Bio-Rad Laboratories, Hercules, CA, USA). Proteins were transferred to nitrocellulose membranes using a semidry blotter (Bio-Rad) and incubated in blocking solution (5% nonfat dry milk in Tris-buffered saline Tween-20 [TBST]) for 1 hour. Membranes were then exposed to primary antibodies overnight at 4°C, and incubated with immunoglobulin G (IgG) horseradish peroxidase (HRP)-conjugated antibody for 1 hour. The blots were washed and visualized by an Immobilon Western Chemiluminescent detection system (Thermo).

### **RANKL ELISA assay**

Mouse marrow stromal cells were isolated as described<sup>(11)</sup> and cultured with 1,25-(OH)<sub>2</sub>D<sub>3</sub> for 7 days. Conditioned media from these cultures were harvested at the end of the culture period and the concentration of RANKL present was determined using an ELISA kit for mouse RANKL (R&D), according to the manufacturer's instructions.

### **Quantitative microcomputed tomography measurements**

The gross morphologic and microarchitectural characteristics of the distal area of the femur and L<sub>5</sub> vertebra were examined by quantitative microcomputed tomography ( $\mu$ CT). The L<sub>5</sub> vertebrae were used for microquantitative CT ( $\mu$ QCT) to assess the trabecular bone, and the femurs were used to measure mean cortical thickness. A three-dimensional (3D) analysis was done to determine bone volume fraction (BV/TV, %), trabecular number (Tb.N, N/ $\mu$ m<sup>2</sup>), trabecular thickness (Tb.Th,  $\mu$ m), and trabecular bone spacing (Tb.Sp,  $\mu$ m). Cortical bone also was analyzed in the femur 2 mm below the growth plate, and the same segmentation parameters were used for analysis.

### **Bone histomorphometric analyses**

Mice were given calcein (10 mg/kg) on day 7 and day 2 prior to euthanasia. Lumbar vertebrae from WT, p62KI/TIL-6, or TIL-6 mice were subjected to qualitative histological examination and histomorphometry. The decalcified sections were stained for TRAP, and OCL containing active TRAP were stained red. The undecalcified sections were left unstained for the evaluation of fluorescent labels. The analysis was performed on the cancellous bone/marrow compartment between the cranial and caudal growth plates in the

vertebral bodies without lesions using the OsteoMeasure XPTM version 1.01 morphometric programs (OsteoMetrics, Inc., Atlanta, GA, USA). Osteoclasts were defined as TRAP-positive mononuclear and multinuclear cells. Osteoclast surface (Oc.S/BS), cancellous bone volume (BV/TV), trabecular thickness (Tb.Th), trabecular number (Tb.N), trabecular separation (Tb.Sp), mineralizing surface (MS/BS), mineral apposition rate (MAR), and bone formation rate (BFR/BS) were analyzed—calculated and expressed—according to the recommendations of the ASBMR Nomenclature Committee.<sup>(17)</sup>

### Isolation of primary osteoblasts

After flushing out the bone marrow from tibias and femora of *p62KI*, *MVNP*, and WT mice, the tibia and femurs were cultured in  $\alpha$ -MEM with 10% FCS for 7 to 10 days. The bones were then placed in 60-mm dishes and the cultures were continued in  $\alpha$ -MEM containing 10% FCS until cells growing out of the bones formed a confluent monolayer. The original bone was removed and the outgrowth cells from the bone were treated with 0.25% Trypsin and 0.05% EDTA for 10 minutes at 37°C. These cells were used as primary osteoblasts without further passage. The primary osteoblasts ( $2 \times 10^5$  cells/well in six-well plates) were cultured in  $\alpha$ -MEM containing 10% FCS for 3 days and then IL-6 or vehicle was added for 4 additional days. Cell lysates were collected with lysate buffer. This isolation method was previously used to establish the MC3T3-E1 cell line.<sup>(18)</sup>

### von Kossa staining

Primary osteoblasts derived from WT, *p62KI*, and *MVNP* mice were cultured in 10% FCS in  $\alpha$ -MEM for 3 weeks with the media changed every 3 days. The cells were then fixed with 10% formaldehyde in PBS, and stained with von Kossa stain as described.<sup>(19)</sup>

### Statistical analysis

For all cell culture studies, significance was evaluated using a two-tailed unpaired Student's *t* test, with  $p < 0.05$  considered to be significant.

## Results

### Characteristics of OCLs from WT, *p62KI*, *TIL-6*, *p62KI/TIL-6*, and *MVNP* mice

OCL precursors in total marrow cultures from *MVNP* mice, and to a lesser extent, *p62KI/TIL-6* mice, were hyperresponsive to 1,25-(OH)<sub>2</sub>D<sub>3</sub> compared to *p62KI*, *TIL-6*, and WT mice, and formed increased numbers of OCLs at  $1 \times 10^{-10}$  to  $1 \times 10^{-8}$  M 1,25-(OH)<sub>2</sub>D<sub>3</sub> (Fig. 1A), suggesting that *p62<sup>P394L</sup>* and *IL-6* can cooperate to promote an increased osteoclastogenic response to 1,25-(OH)<sub>2</sub>D<sub>3</sub>. OCLs from *MVNP* and *p62KI/TIL-6* mice (and to a lesser extent *TIL-6* mice) also had increased numbers of nuclei per OCL when treated with 1,25-(OH)<sub>2</sub>D<sub>3</sub>, compared to those from WT and *p62KI* mice (Fig. 1C, D). OCL precursors in marrow cultures from *MVNP*, *p62KI/TIL-6*, and *p62KI* mice also formed increased numbers of OCLs with RANKL treatment compared to *TIL-6* and WT mice (Fig. 1B), suggesting that IL-6 does not contribute significantly to RANKL responsivity. Bone resorption in response to 1,25-(OH)<sub>2</sub>D<sub>3</sub> ( $1 \times 10^{-8}$  M) and RANKL (100 ng/mL) was comparable in marrow cultures from *MVNP* and *p62KI/TIL6* mice, which were  $> p62KI > TIL-6 > WT$  (Fig. 1E).

### OCL formation by highly purified populations of OCL precursors

OCL formation assays by highly purified populations of OCL precursors showed that only OCL precursors from *TIL-6*, *p62KI/TIL-6*, and *MVNP* mice were hyperresponsive to 1,25-(OH)<sub>2</sub>D<sub>3</sub>, compared to WT and *p62KI* derived cultures (Fig. 2A), demonstrating that the increased 1,25-(OH)<sub>2</sub>D<sub>3</sub> responsivity seen in total marrow cultures from the *p62KI* mice (Fig. 1A) resulted from effects of stromal cells in these cultures. However, the relative OCL formation in response to RANKL by pure populations of OCL precursors was identical to that from the total marrow cultures; ie, OCL precursors from *p62KI*, *p62KI/TIL-6*, and *MVNP* mice were hyperresponsive to RANKL compared to those from *TIL-6* or WT mice (Fig. 2B). The nuclear number per OCL also showed the same pattern of results as seen in OCLs formed from whole marrow cultures (Fig. 2C). These results are consistent with our previous results showing that mutant p62 contributes to RANKL hyperresponsivity directly in OCLs, whereas its contribution to increased 1,25-(OH)<sub>2</sub>D<sub>3</sub> responsivity is mediated through effects on stromal cells.<sup>(11)</sup> In contrast, IL-6 contributes to 1,25-(OH)<sub>2</sub>D<sub>3</sub> responsivity directly in OCLs, but does not appear to have an effect on OCL response to RANKL.

We recently reported that IL-6 induces expression of TAF12, a novel coactivator of VDR-mediated transcription that is increased in OCLs from PD patients and *MVNP* mice.<sup>(20)</sup> Therefore, we determined if TAF12 expression was increased in OCLs from *p62KI*, *TIL-6*, and *p62KI/TIL-6* mice. OCLs formed by highly purified OCL precursors from *TIL-6* and *p62KI/TIL-6* mice expressed elevated levels of TAF12 compared to WT (Fig. 2D). In contrast, TAF12 was not increased in OCLs from *p62KI* mice.

### RANKL expression by marrow stromal cells derived from WT, *p62KI*, *TIL-6*, *p62KI/TIL-6*, and *MVNP* mice

We previously found that marrow stromal cells from *p62KI* but not *MVNP* mice have increased expression of TAF12 which resulted in enhanced RANKL production by the stromal cells when treated with low concentrations of 1,25-(OH)<sub>2</sub>D<sub>3</sub>.<sup>(7,8)</sup> Therefore, we measured RANKL production by stromal cells from *p62KI*, *TIL-6*, *p62KI/TIL-6*, *MVNP*, and WT mice. Stromal cells from *p62KI/TIL-6* and *p62KI* mice treated with 1,25-(OH)<sub>2</sub>D<sub>3</sub> produced increased levels of RANKL when treated with  $1 \times 10^{-10}$  M 1,25-(OH)<sub>2</sub>D<sub>3</sub> (Fig. 3A). Interestingly, *p62KI/TIL-6* stromal cells produced twofold more secreted RANKL than *p62KI* stromal cells (Fig. 3B). Both the RANKL/osteoprotegerin (OPG) ratio (Fig. 3A) and TAF12 levels (Fig. 3C) were markedly increased in stromal cells from *p62KI/TIL-6* mice but not in *MVNP* mice. These results demonstrate that high levels of IL-6 produced by *TIL-6* mice also induce TAF12 in marrow stromal cells, which enhances their responsivity to 1,25-(OH)<sub>2</sub>D<sub>3</sub> and results in increased RANKL production by stromal cells from *p62KI/TIL-6* mice treated with 1,25-(OH)<sub>2</sub>D<sub>3</sub>.

Next we examined if WT, *p62KI*, *TIL-6*, *p62KI/TIL-6*, and *MVNP* stromal cells differentially supported OCL formation. Stromal cells were cocultured with colony-forming unit–granulocytemacrophage (CFU-GM)-derived cells (OCL precursors) from WT mice with  $1 \times 10^{-8}$  M 1,25-(OH)<sub>2</sub>D<sub>3</sub> or vehicle for 7 days. As shown in Fig. 3D, stromal cells derived from *p62KI/TIL-6* mice, and to a lesser extent *p62KI* mice, had an increased

capacity to support OCL formation in response to 1,25-(OH)<sub>2</sub>D<sub>3</sub>. Because stromal cells from MVNP mice do not express increased TAF12, they did not increase OCL formation when cocultured with WT OCL precursors treated with 1,25-(OH)<sub>2</sub>D<sub>3</sub> (Fig. 3D).

### Bone phenotype of *p62KI/TIL-6* mice

To determine whether coexpression of mutant *p62* and *IL-6* in the bone promote the development of pagetic lesions, we examined lumbar vertebral bone from *p62KI*, *TIL-6*, *p62KI/TIL-6*, and WT mice at 12 months of age by qualitative histology and histomorphometry, and femurs and L<sub>5</sub> vertebra by  $\mu$ CT. No pagetic lesions were found in the lumbar vertebrae of any of these mice. Further,  $\mu$ QCT histomorphometric analysis revealed no significant differences between mice of any of the four genotypes in bone structural variables (cancellous BV/TV, Tb.N, Tb.Wi, Tb.Sp) (Table 1), nor in the mineralized surface (Md.Pm), MAR, and BFR (Fig. 4). Only OCL numbers per bone surface were significantly increased in both *p62KI* and *p62KI/TIL-6* mice (Fig. 4).

### Expression of OCL fusion molecules in OCL precursors

Because OCL precursors from MVNP mice and pagetic patients expressing MVNP form OCLs with increased nuclei per OCL, we measured the expression levels of several fusion molecules in MVNP, *p62KI*, and WT OCL precursors treated with IL-6 for 4 days. OCLs formed from MVNP mice with or without IL-6 treatment had elevated expression of dendritic cell-specific transmembrane protein (DC-STAMP) compared with those from *p62KI* and WT mice (Fig. 5). The expression levels of the d2 isoform of the v-ATPase V0 domain (ATP6v0d2) and a distintegrin and a metalloproteinase domain-8 (ADAM8) were only modestly elevated in MVNP OCL (Fig. 5).

### Effect of IL-6 on osteoblast differentiation

Our previous data demonstrated that IL-6 was required to increase bone formation and induce a pagetic phenotype in MVNP mice.<sup>(4)</sup> It was thus our hypothesis that increasing IL-6 expression in OCLs of *p62KI* mice would result in development of a pagetic bone lesions in *p62KI/TIL-6* mice. We therefore examined the effects of IL-6 on osteoblast differentiation by primary osteoblasts from *p62KI*, MVNP, and WT mice.

We found that there was a twofold increase in the levels of Runx2 and Osterix in osteoblasts from MVNP mice compared with WT and *p62KI* mice. These parameters were not affected by IL-6 treatment of WT, MVNP, or *p62KI* osteoblasts (Fig. 6A). In contrast, IL-6 treatment of MVNP osteoblasts modestly enhanced alkaline phosphatase (ALP) expression. The levels of osteocalcin expression were not different in WT, *p62KI*, and MVNP osteoblasts and IL-6 did not increase osteocalcin expression (Fig. 6A). Because high expression levels of Dickkopf 1 (Dkk1) can inhibit osteoblast differentiation,<sup>(21)</sup> we measured Dkk1 levels in WT, *p62KI*, and MVNP osteoblasts. Dkk1 expression in *p62KI* osteoblasts was elevated twofold and increased to 3.8-fold with IL-6 treatment (Fig. 6A). In contrast, MVNP and WT osteoblasts had much lower levels of Dkk1 that were not affected by IL-6 treatment (Fig. 6A). Osteoblast (OB)-cadherin and ALP were decreased in the *p62KI* mice compared to WT and MVNP, and were inversely correlated with Dkk1 expression, which was elevated in

*p62*KI compared to WT and *MVNP*; *RUNX2* and osterix were induced twofold in *MVNP* mice.

We then measured the mineral deposition capacity of the osteoblasts by von Kossa staining. *MVNP* osteoblast cultures showed increased numbers of calcified areas compared with cultures of *p62*KI and WT osteoblasts (Fig. 6B). These results suggest that the osteoblast differentiation capacity of osteoblast from *p62*KI mice is much lower than osteoblast from *MVNP* mice.

## Discussion

Both environmental elements and genetic causes both contribute to PD. We found that the expression of both *MVNP* and the *SQSTM1* (*p62*) mutation *P392L* in OCLs contribute to the increased OCL activity in PD, and we have reported that *p62*<sup>P392L</sup> knock-in mice do not develop pagetic lesions unless *MVNP* is also present. When *MVNP* is present with the *p62*KI mutation, mice develop exuberant pagetic lesions very similar to those seen in patients with PD of bone. However, Daroszewska and colleagues<sup>(22)</sup> reported that a similar *p62*<sup>P394L</sup> knock-in mouse develops small focal lesions which showed increases in bone turnover with increased bone resorption and formation, disruption of the normal bone architecture, and an accumulation of woven bone. The basis for the differences in these two knock-in models is unclear at this time but demonstrate that the capacity of mutant *p62* to induce pagetic lesions in vivo is variable. *MVNP*, but not *p62*KI, mice have increased IL-6 production and loss of IL-6 blocks the effects of *MVNP* in PD.<sup>(9,11,12)</sup> These results suggest *p62*KI in combination with high IL-6 in OCL may result in PD. To address this question, we generated *p62*KI/*TIL-6* transgenic mice by breeding *p62*KI mice to *TIL-6* mice in which overexpression of IL-6 is driven by the TRAP promoter, and characterized their OCLs and bone phenotype.

OCL precursors from *p62*KI/*TIL-6* mice formed OCL that expressed an intermediate pagetic phenotype in vitro (Fig. 1). The OCLs were hyperresponsive to 1,25-(OH)<sub>2</sub>D<sub>3</sub> and RANKL, formed OCL with increased bone resorbing capacity and elevated levels of TAF12 but developed only modest multinuclearity (Figs. 1, 2) compared to *MVNP* mice.

In contrast, OCL precursors from *p62*KI and WT mice were not hyperresponsive to 1,25-(OH)<sub>2</sub>D<sub>3</sub>, expressed normal levels of TAF12, and formed normal OCLs.<sup>(11)</sup> Only OCL precursors from *p62*KI/*TIL-6* were hyperresponsive to RANKL, whereas both *p62*KI/*TIL-6* and *TIL-6* cells had increased STAT3 signaling (Fig. 2D). *p62*KI and WT OCL had normal ratios of nuclei/OCL when treated with 1,25-(OH)<sub>2</sub>D<sub>3</sub> or RANKL. These results suggested that expression of IL-6 in *p62*KI OCL precursors is required for OCLs to express a pagetic phenotype in vitro, and that high levels of IL-6 enhances OCL precursor fusion in *p62*KI mice. The enhanced OCL precursor fusion in *MVNP* mice most likely reflects the increased expression of DC-STAMP<sup>(23,24)</sup> in their OCL precursors, which was enhanced by IL-6 treatment (Fig. 5). DC-STAMP appears to be increased selectively in *MVNP* OCL precursors compared with other fusion molecules associated with increased OCL precursor fusion (eg, D44, CD48, and ADAM8), and was not increased significantly in *p62*KI and WT OCL precursors (Fig. 5). Lee and colleagues<sup>(25)</sup> reported that increased nuclear factor of



activated T cells, cytoplasmic 1 (NFATc1) through upregulation of c-Fos increased expression of DC-STAMP. Because IL-6 increases expression of c-Fos and NFATc1, this may explain its capacity to enhance DC-STAMP expression. ATP6v0d2 also was upregulated modestly (1.8-fold) in MVNP OCL precursors. This mostly reflects that NFATc1 can also enhance expression of this fusion molecule.<sup>(26)</sup> Further, IL-6 enhances p38 mitogen-activated protein kinase (MAPK) signaling in MVNP OCL precursors (data not shown), which may also contribute to the hypermultinuclearity of OCLs formed in marrow cultures from MVNP mice. We previously reported that enhanced p38 MAPK signaling plays a critical role in the increased nuclear number per OCL in OCLs expressing the measles virus nucleocapsid gene.<sup>(9)</sup>

Marrow stromal cells from *p62KI/TIL-6* expressed higher levels of RANKL in response to 1,25-(OH)<sub>2</sub>D<sub>3</sub> than the other mouse marrow stromal cells (Fig. 3A). The RANKL/OPG expression ratio in stromal cells from *p62KI/TIL-6* was increased 3.5-fold compared with WT (Fig. 3A). The stromal cells from *p62KI/TIL-6* also expressed high levels of TAF12. The expression of TAF12 in stromal cells can result in hyperresponsivity to 1,25-(OH)<sub>2</sub>D<sub>3</sub> and increased VDR transcription because at high levels, TAF12 acts as a coactivator of VDR transcription.<sup>(20)</sup> Why *p62KI/TIL-6* had higher expression of RANKL compared with *p62KI* stromal cells is not clear. Possibly, *p62<sup>P394L</sup>* and IL-6 have additive effects on VDR-TAF12 mediated transcription. These findings may in part explain the enhanced RANKL production present in the marrow microenvironment of pagetic patients.

*p62KI/TIL-6* mice did not develop pagetic bone lesions or structural characteristics seen in pagetic patients. They only had increased OCL perimeter scores (Fig. 4A). In contrast, dynamic bone formation variables were similar to those in WT mice (Fig. 4, Table 1). These results suggest IL-6 is not enhancing osteoblast activity. Franchimont and colleagues<sup>(27)</sup> report that IL-6 can modulate osteoblast proliferation, differentiation, and apoptosis, and supports osteoblast generation. However, as shown in Fig. 6, IL-6 only increased ALP expression in osteoblasts from MVNP mice. These results suggest high levels of IL-6 are not sufficient to induce the enhanced bone formation characteristic of PD.

Interestingly, *p62KI* osteoblasts had increased expression of the Wnt signaling antagonist, Dkk1, which was further increased by IL-6 (Fig. 6A). Naot and colleagues<sup>(28)</sup> reported increased expression of Dkk1 in osteoblast cultures from Paget's patients. The canonical Wnt pathway plays a key role in regulating osteoblast proliferation and differentiation.<sup>(29)</sup> Tian and colleagues<sup>(21)</sup> have suggested that the release of Dkk1 from malignant plasma cells in multiple myeloma results in an inhibition of osteoblast proliferation, accentuating the imbalance between bone formation and bone resorption and facilitating local bone loss. In the *p62KI/TIL-6* mice, overproduction of Dkk1 in osteoblasts could have a similar effect on bone formation. Possibly increased levels of IL-6 are responsible for the overexpression of Dkk1 in PD and contribute to the development of the lytic phase of PD through further accelerating local bone turnover. These results may explain in part why *p62KI/TIL-6* mice did not develop pagetic lesions in vivo.

In summary, these results demonstrate that *p62<sup>P394L</sup>* and IL-6 in combination increase OCL formation and activity, but are not sufficient to induce pagetic OCL and bone lesions

characteristic of PD in vivo. Further, based on our findings that loss of IL-6 in *MVNP* mice results in loss of their pagetic phenotype, these results demonstrate that IL-6 is necessary but not sufficient to induce PD. These data further demonstrate that expression of high IL-6 in OCL confers many of characteristics of PD OCL (hyperresponsivity to 1,25-(OH)<sub>2</sub>D<sub>3</sub>, increased nuclei/OCL, increased bone resorption) but is not sufficient by itself or in combination with *p62<sup>P394L</sup>* to induce PD. Thus, other factors induced by *MVNP* may also be required to enhance bone formation characteristics of PD, such as coupling factors or osteoblast stimulating factors. Recently, we found that *MVNP* but not *p62<sup>P394L</sup>* increased expression of ephrinB2/EphB4, insulin-like growth factor 1 (IGF1), and semaphorin3A, suggesting *MVNP* has multiple effects beyond upregulating IL-6 to induce PD (ASBMR 2013 Abstract).<sup>(30)</sup>


## Acknowledgments

This work was supported by R01-AR057308 (to GDR) and R01-AR057310 (to DLG) from NIH-NIAMS, 5P30CA016059 (to JJW) from NIH/NCI Cancer Center support grant, and W81XWH-12-1-0533 (to NK) from Department of Defense. This research project was provided the VCU transgenic/knockout Mouse Shared Resource.


## References

- Hosking DJ. Paget's disease of bone. *Br Med J (Clin Res Ed)*. 1981; 283:686–8.
- Kanis JA, Simon LS. Metabolic consequences of bone turnover in Paget's disease of bone. *Clin Orthop*. 1987; 217:26–36. [PubMed: 3549093]
- Siris ES, Roodman GD. Paget's Disease of Bone, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Chapter 80. American Society for Bone and Mineral. 2013:659–669.
- Roodman GD, Kurihara N, Ohsaki Y, et al. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. *J Clin Invest*. 1992; 89:46–52. [PubMed: 1729280]
- Hoyland JA, Freemont AJ, Sharpe PT. Interleukin-6, IL-6 receptor, and IL-6 nuclear factor gene expression in Paget's disease. *J Bone Miner Res*. 1994; 1:75–80. [PubMed: 8154312]
- Roodman GD, Windle JJ. Paget disease of bone. *J Clin Invest*. 2005; 115:200–8. [PubMed: 15690073]
- Kurihara N, Reddy SV, Mena C, et al. Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype. *J Clin Invest*. 2000; 105:607–14. [PubMed: 10712432]
- Kurihara N, Zhou H, Reddy SV, et al. Expression of measles virus nucleocapsid protein in osteoclasts induces Paget's disease-like bone lesions in mice. *J Bone Miner Res*. 2006; 21:446–55. [PubMed: 16491293]
- Kurihara N, Hiruma Y, Yamana K, et al. Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease. *Cell Metab*. 2011; 13:23–34. [PubMed: 21195346]
- Sundaram K, Shanmugarajan S, Rao DS, et al. Mutant p62<sup>P392L</sup> stimulation of osteoclast differentiation in Paget's disease of bone. *Endocrinology*. 2011; 152:4180–9. [PubMed: 21878516]
- Hiruma Y, Kurihara N, Subler MA, et al. A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment. *Hum Mol Genet*. 2008; 17:3708–19. [PubMed: 18765443]
- Kurihara N, Hiruma Y, Zhou H, et al. Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. *J Clin Invest*. 2007; 117:133–42. [PubMed: 17187080]
- Reddy SV, Scarcez T, Windle JJ, et al. Cloning and characterization of the 5'-flanking region of the mouse tartrate-resistant acid phosphatase gene. *J Bone Miner Res*. 1993; 8:1263–70. [PubMed: 8256664]


14. Reddy SV, Hundley JE, Windle JJ, et al. Characterization of the mouse tartrate resistant acid phosphatase (TRAP) gene promoter. *J Bone Miner Res.* 1995; 4:601–6. [PubMed: 7610931]
15. Nagy, A.; Gertsenstein, M.; Vintersten, K., et al. *A laboratory manual.* 3rd ed. CSHL Press; Cold Spring Harbor, NY: 2003. Manipulating the mouse embryo.
16. Ishizuka H, García-Palacios V, Lu G, et al. ADAM8 enhances osteoclast precursor fusion and osteoclast formation in vitro and in vivo. *J Bone Miner Res.* 2011; 26:169–81. [PubMed: 20683884]
17. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. *J Bone Miner Res.* 1987; 2:595–610. [PubMed: 3455637]
18. Sudo H, Kodama HA, Amagai Y, et al. In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. *J Cell Biol.* 1983; 96:191–8. [PubMed: 6826647]
19. Meloan SN, Puchtler H. Chemical mechanisms of staining methods: von Kossa's technique. What von Kossa really wrote and a modified reaction for selective demonstration of inorganic phosphate. *J Histotechnol.* 1985; 8:11–3.
20. Kurihara N, Reddy SV, Araki N, et al. Role of TAFII-17, a VDR binding protein, in the increased osteoclast formation in Paget's disease. *J Bone Miner Res.* 2004; 19:1154–64. [PubMed: 15176999]
21. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. *N Engl J Med.* 2003; 349:2483–94. [PubMed: 14695408]
22. Daroszewska A, van't Hof RJ, Rojas JA, et al. A point mutation in the ubiquitin-associated domain of SQSMT1 is sufficient to cause a Paget's disease-like disorder in mice. *Hum Mol Genet.* 2011; 20:2734–44. [PubMed: 21515589]
23. Yagi M, Miyamoto T, Sawatani Y, Iwamoto K, et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. *J Exp Med.* 2005; 202:345–51. [PubMed: 16061724]
24. Yagi M, Miyamoto T, Toyama Y, Suda T. Role of DC-STAMP in cellular fusion of osteoclasts and macrophage giant cells. *J Bone Miner Metab.* 2006; 24:355–8. [PubMed: 16937266]
25. Lee MS, Kim HS, Yeon JT, et al. GM-CSF regulates fusion of mononuclear osteoclasts into bone-resorbing osteoclasts by activating the Ras/ERK pathway. *J Immunol.* 2009; 183:3390–9. [PubMed: 19641137]
26. Kim K, Lee SH, Ha Kim J, et al. NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). *Mol Endocrinol.* 2008; 22:176–8. [PubMed: 17885208]
27. Franchimont N, Wertz S, Malaise M. Interleukin-6: an osteotropic factor influencing bone formation? *Bone.* 2005; 37:601–6. [PubMed: 16112634]
28. Naot D, Bava U, Matthews B, et al. Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone. *J Bone Miner Res.* 2007; 22:298–309. [PubMed: 17129176]
29. Gong Y, Slee RB, Fukai N, et al. Osteoporosis-Pseudoglioma Syndrome Collaborative Group. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. *Cell.* 2001; 107:513–23. [PubMed: 11719191]
30. Kurihara N, Teramachi J, Kitagawa Y, et al. IFGI contributes to the increased bone formation by measles virus nucleocapsid protein expressed by osteoclasts in Paget's Bone Disease. *J Bone Miner Res.* 2013; 28(sup 1) (Abstract #FR440).




**Fig. 1.** Osteoclast formation in whole bone marrow cultures from WT, *p62KI*, *TIL-6*, *p62KI/TIL-6*, and *MVNP* mice. (A) OCL formation by treatment of 1,25-(OH)<sub>2</sub>D<sub>3</sub>. Data are expressed as the mean ± SD (*n* = 4); \**p* < 0.01, significantly different from OCLs formed with the same treatment in WT mouse cultures. (B) OCL formation by treatment of RANKL. Data are expressed as the mean ± SD (*n* = 4); \**p* < 0.01, significantly different from OCLs formed with the same treatment in WT mouse cultures. (C) Phenotype of OCLs formed from mouse bone marrow cultures. OCLs formed by 1,25-(OH)<sub>2</sub>D<sub>3</sub> (1 × 10<sup>-8</sup> M) were stained for TRAP. Magnification ×100. (D) Nuclei per OCL. The nuclear numbers per OCL were randomly counted in 25 OCLs formed in 1 × 10<sup>-8</sup> M 1,25-(OH)<sub>2</sub>D<sub>3</sub> or 100 ng/mL RANKL-treated cultures as in A and B. Data are expressed as the mean ± SD (*n* = 25); \**p* < 0.01, significantly different from OCLs formed with the same treatment in WT mouse cultures. (E) Bone resorption capacity of OCLs. Bone marrow cells were cultured for 7 days with 1,25-(OH)<sub>2</sub>D<sub>3</sub> (1 × 10<sup>-8</sup> M) or RANKL (100 ng/mL) on mammoth dentin slices. Values represent the amount of dentin surface resorption (%), mean ± SD (*n* = 4). WT = wild = type; OCL = osteoclast; 1,25-(OH)<sub>2</sub>D<sub>3</sub> = 1,25-dihydroxyvitamin D<sub>3</sub>; TRAP = tartrate-resistant acid phosphatase; RANKL = receptor activator of NF-κB ligand.



**Fig. 2.** Osteoclast formation formed by CD11b<sup>+</sup> cells from WT, p62KI, TIL-6, p62KI/TIL-6, and MVNP mice. (A) OCL formation by 1,25-(OH)<sub>2</sub>D<sub>3</sub>. Data are expressed as the mean ± SD (n = 4); \*p < 0.01, significantly different from OCLs formed with the same treatment in WT mouse cultures. (B) OCL formation by RANKL. Data are expressed as the mean ± SD (n = 4); \*p < 0.01, significantly different from OCLs formed with the same treatment in WT mouse cultures. (C) Nuclei per OCL. The nuclear number per OCL was determined by randomly scoring 25 OCLs formed in 1 × 10<sup>-8</sup> M 1,25-(OH)<sub>2</sub>D<sub>3</sub> or 100 ng/mL of RANKL-treated cultures. Data are expressed as the mean ± SD (n = 25); \*p < 0.01, significantly different from OCLs formed with the same treatment in WT mouse cultures. (D) TAF12 expression in OCLs. CD11b<sup>+</sup> mononuclear cells were treated with 10 ng/mL of M-CSF for 3 days, then cultured with RANKL (100 ng/mL) for 4 days and cell lysates were collected. TAF12 expression was analyzed by immunoblot using antibodies recognizing TAF12 (ProteinTech). TFIIB was used as a loading control. WT = wild-type; RANKL = receptor activator of NF-κB ligand; OCL = osteoclast; 1,25-(OH)<sub>2</sub>D<sub>3</sub> = 1,25-dihydroxyvitamin D<sub>3</sub>; M-CSF = macrophage colony-stimulating factor; TFIIB = transcription factor IIB.


**Fig. 3.**

Support of OCL formation by marrow stromal cells from WT, *p62KI*, *TIL-6*, *p62KI/TIL-6*, and *MVNP* mice. (A) RANKL and OPG expression. Stromal cells from WT, *p62KI*, *TIL-6*, *p62KI/TIL-6*, and *MVNP* mice were cultured with 1,25-(OH)<sub>2</sub>D<sub>3</sub> ( $1 \times 10^{-8}$  M) for 2 days, the cell lysates were collected, and the levels of RANKL and OPG were determined by Western blot analysis using anti-RANKL and anti-OPG antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The ratio of RANKL/OPG expression levels from Western blots were quantitated by densitometry using WT cultures as 1.0. (B) RANKL production by mouse marrow stromal cells. Mouse marrow stromal cells were cultured with 1,25-(OH)<sub>2</sub>D<sub>3</sub> for 7 days. Conditioned media from these cultures were harvested at the end of the culture period and the concentration of RANKL present was determined. The data is shown as mean  $\pm$  SD ( $n = 4$ ); \* $p < 0.01$  compared with WT cells cultured with the same concentration of 1,25-(OH)<sub>2</sub>D<sub>3</sub>. (C) TAF12 expression in marrow stromal cells. Stromal cells were cultured with 10% FCS in IMDM for 3 days and then cell lysates were collected. TAF12 expression was analyzed by immunoblot using a polyclonal antibody recognizing TAF12. TFIIIB was used as a loading control. (D) Support of OCL formation by marrow stromal cells. Stromal cells from WT, *p62KI*, *TIL-6*, *p62KI/TIL-6*, and *MVNP* mice were cocultured with CFU-GM derived from WT mouse bone marrow in the presence of  $1 \times 10^{-8}$  M 1,25-(OH)<sub>2</sub>D<sub>3</sub> for 7 days. The cells were then fixed and stained for TRAP, and the TRAP-positive OCLs were counted. Results are expressed as the mean  $\pm$  SD ( $n = 4$ ); \* $p < 0.01$  compared with results in WT cultures. OCL = osteoclast; WT = wild-type; RANKL = receptor activator of NF- $\kappa$ B ligand; OPG = osteoprotegerin; 1,25-(OH)<sub>2</sub>D<sub>3</sub> = 1,25-dihydroxyvitamin D<sub>3</sub>; FCS = fetal calf serum; IMDM = Iscove's Modified Dulbecco's Media; TFIIIB = transcription factor IIB; CFU-GM = colony-forming unit-granulocytemacrophage; TRAP = tartrate-resistant acid phosphatase.



**Fig. 4.**


Histomorphometric analysis of WT, *TIL-6*, *p62KI*, and *p62KI/TIL-6* lumbar vertebra from 12-month-old. (A) OC.Pm, (B) Md.Pm, (C) MAR, and (D) BFR for WT, *TIL-6*, *p62KI*, and *p62KI/TIL-6* mice are shown. Data represent mean  $\pm$  SD for WT (7 male, 7 female), *p62KI* (6 male, 7 female), *TIL-6* (7 male, 10 female), and *p62KI/TIL-6* (3 male, 10 female) mice per group. \* $p < 0.01$  significant differences between WT and *p62KI/TIL-6* mice were detected. WT = wild-type; OCL = osteoclast; OC.Pm = OCL surface; Md.Pm = mineralized surface; MAR = mineral apposition rate; BFR = bone formation rate.



**Fig. 5.**

The expression of fusion molecules in WT, *p62KI*, and *MVNP* OCL precursors. CD11b<sup>+</sup> mononuclear cells were treated with 10 ng/mL M-CSF for 3 days, then treated with or without mouse IL-6 (10 ng/mL) (R&D) and mouse IL-6 receptor (10 ng/mL) (R&D) for 4 days. Cell lysates were analyzed by immunoblot using antibodies recognizing DC-STAMP (Cosmo Bio Co. Ltd, Tokyo, Japan), ATP6v0d2 (Abnova Co., Taipei, Taiwan), ADAM8 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and  $\beta$ -actin (Abcam, Cambridge, MA, USA) as a loading control. WT = wild-type; OCL = osteoclast; M-CSF = macrophage colony-stimulating factor; IL-6 = interleukin 6; DC-STAMP = dendritic cell-specific transmembrane protein; ATP6v0d2 = the d2 isoform of the v-ATPase V0 domain; ADAM8 = a disintegrin and a metalloproteinase domain-8.





**Fig. 6.** Osteoblast differentiation markers in osteoblasts derived from WT, *p62KI*, and *MVNP* mice. (A) Expression of osteoblast differentiation markers. Primary osteoblasts ( $2 \times 10^5$  cells/35-mm dish) were cultured with or without 10 ng/mL of IL-6 for 4 days in 10% FCS in  $\alpha$ -MEM. Cell lysates were analyzed by immunoblot using antibodies recognizing OB-Cadherin (Cell Signaling, Beverly, MA, USA), alkaline phosphatase (Millipore, Billerica, MA, USA), Runx2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), Osterix (Abcam, Cambridge, MA, USA), osteocalcin (Millipore), Dkk1 (Cell Signaling), and  $\beta$ -actin (Abcam) as loading control. (B) Calcification in vitro. Osteoblasts were cultured in 10% FCS with  $\alpha$ -MEM for 3 weeks as described in Subjects and Methods. The cells were stained with von Kossa stain ( $\times 100$ ). WT = wild-type; IL-6 = interleukin 6; FCS = fetal calf serum;  $\alpha$ -MEM =  $\alpha$  modified essential medium.

**Table 1**Structural Histomorphometric Variables of WT, *TIL-6*, *p62KI*, and *p62KI/TIL-6* Mice

	Male				Female			
	WT (n = 7)	<i>TIL-6</i> (n = 7)	<i>p62KI</i> (n = 6)	<i>p62KI/TIL-6</i> (n = 3)	WT (n = 7)	<i>TIL-6</i> (n = 10)	<i>p62KI</i> (n = 7)	<i>p62KI/TIL-6</i> (n = 10)
BV/TV (%)	13.4±2.1	13.1±5.9	13.5±5.8	14.6±4.5	13.3±5.6	11.9±4.3	10.2±2.5	11.2±3.9
Tb.Th (µm)	31.4±3.1	33.1±5.6	36.2±8.5	33.1±5.0	33.3±4.5	35.5±5.3	35.5±3.6	37.1±9.8
Tb.N (1/mm <sup>2</sup> )	4.3±0.4	3.8±1.1	3.7±1.3	4.4±0.9	4.0±1.6	3.5±1.7	2.9±0.6	3.0±0.1
Tb.Sp (µm)	204.4±22.3	248.1±86.0	265.4±121.9	203.0±48.1	239.6±73.0	312.0±169.1	327.1±84.3	313.0±84.2

Structural variables for the lumbar vertebral bodies from 12-month-old WT, *p62KI*, *TIL-6*, and *p62KI/TIL-6* mice. Data are expressed as mean ± SD. No significant differences between WT and other mice in all the variables.

WT = wild-type; BV/TV = cancellous bone volume; Tb.Th = trabecular thickness; Tb.N = trabecular number; Tb.Sp = trabecular separation.